KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Tax Provisions (2017 - 2025)

Amneal Pharmaceuticals (AMRX) has 9 years of Tax Provisions data on record, last reported at $5.7 million in Q4 2025.

  • For Q4 2025, Tax Provisions rose 4.41% year-over-year to $5.7 million; the TTM value through Dec 2025 reached $11.3 million, down 40.22%, while the annual FY2025 figure was $11.3 million, 40.22% down from the prior year.
  • Tax Provisions reached $5.7 million in Q4 2025 per AMRX's latest filing, up from -$23.4 million in the prior quarter.
  • Across five years, Tax Provisions topped out at $16.1 million in Q2 2025 and bottomed at -$23.4 million in Q3 2025.
  • Average Tax Provisions over 5 years is $3.0 million, with a median of $4.0 million recorded in 2021.
  • Peak YoY movement for Tax Provisions: soared 2711.81% in 2021, then tumbled 975.0% in 2022.
  • A 5-year view of Tax Provisions shows it stood at $4.1 million in 2021, then plummeted by 144.84% to -$1.8 million in 2022, then skyrocketed by 636.02% to $9.9 million in 2023, then plummeted by 44.96% to $5.4 million in 2024, then increased by 4.41% to $5.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Tax Provisions were $5.7 million in Q4 2025, -$23.4 million in Q3 2025, and $16.1 million in Q2 2025.